Insulet Corporation (PODD) PT Raised to $300 at Jefferies After Earnings
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Jefferies analyst Raj Denhoy raised the price target on Insulet Corporation (NASDAQ: PODD) to $300.00 (from $265.00) after the company posted a $14mn top-line beat as new patients improved to -10% of pre-COVID levels (-25% last Q). Initial guidance calls for 21-25% US OmniPod (midpoint 300bps ahead of Street) driven by DASH, continued MDI gains, and the OmniPod 5 (CGM integrated) soft launch.
The analyst reiterated the Buy rating, stating "Although valuation is rich, the premium is well-deserved as PODD is among the best positioned to benefit from the coming automation wave across diabetes." He went on to state "Several headlines will serve as future growth drivers over the next 12-18 months, including: 1) readout of pre-school pivotal study and FDA submission, 2) readout of T2 feasibility study, 3) launch of O5 compatible with Abbott (ABT, Buy) Libre, and 5) launch of O5 with control from iOS phones."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlueScope Steel Limited (BSL:AU) (BLSFY) PT Raised to AUD22.50 at Credit Suisse
- Hoshizaki Corp. (6465:JP) PT Raised to JPY8,200 at Morgan Stanley
- Babcock International Group Plc (BAB:LN) (BCKIF) PT Raised to GBP2.60 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Hot Comments
Related EntitiesJefferies & Co, Earnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!